From who owns the San Francisco 49ers to when they play next. Here's what to know about the five time Super Bowl championship ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched ...

Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...

These five high-yield dividend stocks with solid upside potential and Buy ratings make sense for growth and income investors ...

Given the stock's less-than favorable performance during the last few years as it emerged from its pandemic growth days and ...

Quick Read Enbridge plans to add $8B in new projects next year to boost cash flow and dividend capacity. Pfizer generated $14B in free cash flow this year. Its Seagen and Metsera acquisitions target ...

Pfizer (PFE) on Tuesday announced that a patient who was taking part in a long-term extension trial for its hemophilia therapy Hympavzi (marstacimab) died after serious adverse events. The patient ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several hemophilia advocacy groups confirmed this week. Pfizer is now working with its ...

The U.S. Food and Drug Administration (FDA) has approved a major safety update to the label of Depo-Provera, a widely used birth control injection. Nearly 2,000 women have filed lawsuits against ...

And do they now do nuclear fusion too? And do they now do nuclear fusion too? is a news editor with over a decade’s experience in journalism. He previously worked at Android Police and Tech Advisor.